.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: RE43879

« Back to Dashboard
Patent RE43879 protects FETZIMA and is included in one NDA.

This patent has thirty-nine patent family members in twenty-six countries.

Summary for Patent: RE43879

Title:Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Abstract: The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent or to treat disorders that can be managed by double inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity.
Inventor(s): Deregnaucourt; Jean (Paris, FR), Grosse; Richard (Gidy, FR)
Assignee: Pierre Fabre Medicament (Paris, FR)
Application Number:13/406,415
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Forest Labs Inc
FETZIMA
levomilnacipran hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL204168-001Jul 25, 2013RXNoRE43879► subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Forest Labs Inc
FETZIMA
levomilnacipran hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL204168-002Jul 25, 2013RXNoRE43879► subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Forest Labs Inc
FETZIMA
levomilnacipran hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL204168-003Jul 25, 2013RXNoRE43879► subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: RE43879

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France03 01849Feb 14, 2003

Non-Orange Book Patents for Patent: RE43879

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,074,833Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug► subscribe
7,005,452Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: RE43879

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria401872► subscribe
Austria501716► subscribe
Australia2004216452► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc